Cargando…
MODL-16. ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
BACKGROUND: Glial-lineage tumors constitute a heterogeneous group of neoplasms, comprising gliomas, oligodendrogliomas, and ependymomas, which account for 40%–50% of all pediatric central nervous system tumors. Advances in modern neuro-oncological therapeutics are aimed at improving neoadjuvant chem...
Autores principales: | Liang, Muh-Lii, Hsieh, Tsung-Han, Wong, Tai-Tong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715793/ http://dx.doi.org/10.1093/neuonc/noaa222.590 |
Ejemplares similares
-
MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors
por: Guadix, Sergio, et al.
Publicado: (2022) -
MODL-02. TARGETING REPLICATION STRESS IN PEDIATRIC BRAIN TUMORS
por: Krausert, Sonja, et al.
Publicado: (2020) -
MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
por: Sommerkamp, Alexander C, et al.
Publicado: (2020) -
MODL-01. Targeting replication stress in pediatric brain tumors
por: Krausert, Sonja, et al.
Publicado: (2022) -
MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)